Oral peptide delivery: Technology landscape & current status

ONdrugDelivery

Volumn 2015, Issue 59, 2015, Pages 12-17

  Hassani, Leila N ^a   Lewis, Andy ^a   Richard, Joël ^a  

^a IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GOLD NANOPARTICLE; PEPTIDASE; PEPTIDE;

DRUG ABSORPTION; DRUG DELIVERY SYSTEM; HUMAN; PATHOPHYSIOLOGY; PHARMACEUTICS; PHARMACOLOGY; PHYSIOLOGY; REVIEW;

EID: 84936090736     PISSN: 2049145X     EISSN: 20491468     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (25)

1. Lewis AL, Richard J, “Challenges in the delivery of peptide drugs: an industry perspective”. Ther Del, 2015, Vol 6(2), pp 149-163
2. Reynolds L, McKee M, “Serve the people or close the sale? Profit-driven overuse of injections and infusions in China’s market-based healthcare system”. Int J Health Planning Management, 2011, Vol 26(4), pp 449-470
3. Flood EM, Ryan KJ, Rousculp MD, Beusterien KM, Block SL, Hall MC, Mahadevia PJ, “A survey of children’s preferences for influenza vaccine attributes”. Vaccine, 2011, Vol 29(26), pp 4334-4340
4. Anilkumar P, Badarinath A, Naveen N, Prasad K, Reddy BRS, Hyndhavi M, Nirosha M, “A rationalized description on study of intestinal barrier, drug permeability and permeation enhancers”. J Global Trends Pharm Sci, 2011, Vol 2(4), pp 431-449
5. Thanou M, Verhoef JC, Junginger HE, “Oral drug absorption enhancement by chitosan and its derivatives”. Adv Drug Del Rev, 2001, Vol 52(2), p 117-126
6. Xia WJ, Onyuksel H, “Mechanistic studies on surfactant-induced membrane permeability enhancement”. Pharm Res, 2000, Vol 17(5), pp 612-618
7. Pridgen EM, Alexis F, Kuo TT, Levy-Nissenbaum E, Karnik R, Blumberg RS, Langer R, Farokhzad OC, “Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery”. Sci Translat Med, 2013, Vol 5(213), 213ra167
8. Sakai M, Imai T, Ohtake H, Azuma H, Otagiri M, “Simultaneous Use of Sodium Deoxycholate and Dipotassium Glycyrrhizinate Enhances the Cellular Transport of Poorly Absorbed Compounds Across Caco- 2 Cell Monolayers”. J Pharmacy Pharmacol, 1999, Vol 51(1), pp 27-33
9. Prego C et al “The potential of chitosan for the oral administration of peptides”. Expert Opin Drug Del, 2005, Vol 2(5), pp 843-854
10. Bernkop-Schnürch A, Pinter Y, Guggi D, Kahlbacher H, Schöffmann G, Schuh M, Schmerold I, Del Curto MD, D’Antonio M, Esposito P, Huck C, “The use of thiolated polymers as carrier matrix in oral peptide delivery— Proof of concept”. J Control Rel, 2005, Vol 106(1-2), pp 26-33
11. Goldberg M, Gomez-Orellana I, “Challenges for the oral delivery of macromolecules”. Nat Rev Drug Discov, 2003, Vol 2(4), pp 289-295
12. Agarwal V, Nazzal S, Reddy IK, Khan MA, “Transport studies of insulin across rat jejunum in the presence of chicken and duck ovomucoids”. J Pharmacy Pharmacol, 2001, Vol 53(8), pp 1131-1138
13. Binkley N, Bolognese M, Sidorowicz- Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, “For the Oral Calcitonin in Postmenopausal Osteoporosis I: A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial”. J Bone Mineral Res, 2012, Vol 27(8), pp 1821-1829
14. Mehta N, “Clinical Development of an Oral Formulation of Recombinant Salmon Calcitonin”. The Peptide Conference, 2010, Cambridge, UK
15. Henriksen K, Andersen J, Riis B, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard B, Teglbjaerg C, “Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH (1–31) NH 2] in postmenopausal women with osteoporosis”. Bone, 2013, Vol 53(1), pp 160-166
16. Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, Landau I, Karmeli I, Bidlingmaier M, Strasburger CJ, Kleinberg DL et al, “Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression”. J Clin Endocrinol Metabol, 2012, Vol 97(7), pp 2362-2369
17. Melmed S, Popovic V, Bidlingmaier M, Mercado M, Van Der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, “Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial”. J Clin Endocrinol Metabol, 2015, Vol 100(4), pp 1699-1708
18. Press Release, Merrion Pharmaceuticals, March 4, 2015 (http://merrionpharma.com/content/investors/archive/2014/040314.asp)
19. Press Release, Emisphere Technologies, May 1, 2009 (http://ir.emisphere.com/releasedetail.cfm?ReleaseID=381129)
20. Press Release, Emisphere Technologies, March 19, 2015 (http://ir.emisphere.com/releasedetail.cfm?ReleaseID=902461)
21. Eldor R, Arbit E, Corcos A, Kidron M, “Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study”. PloS one, 2013, Vol 8(4):e59524
22. Lee W, “Therapeutic calcium phosphate particles and methods of making and using same”. US Patent Application US20010048925 A1
23. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B, “Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet”. Diabetes Care, 1996, Vol 19(8), pp 843-848
24. Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahren B, “GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions”. Diabetes Care, 1997, Vol 20(12), pp 1874-1879
25. Company Web Page, Rani Therapeutics, 2015, (http://www.ranitherapeutics.com/)